About
Convert Pharmaceuticals develops hypoxia-activated prodrugs that remain inactive until they reach tumor microenvironments, aiming to improve cancer treatment by targeting tumor hypoxia in various solid tumors.
Explore Convert Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.